ENGN Stock Forecast & Price Target

enGene Therapeutics is viewed positively because detalimogene could secure an accelerated approval pathway while fitting the practical needs of community urology practices, where ease-of-use, safety, reduced dwell time, and lower administration burden are key decision factors. The company has already shown a 54% CR anytime rate and a 25% 12-month CR Kaplan-Meier estimate at AUA 2026, with up to 21 patients still able to contribute to the 12-month analysis in 4Q26, leaving room for durability to improve as the pivotal cohort matures. Supportive payer feedback tied to NCCN guideline inclusion, plus the cleared safety run-in for the detalimogene plus surfactant cohort and expected mid-October 2026 enrollment guidance, further reinforce the commercial and regulatory case.

enGene Therapeutics is a high-risk clinical-stage biotech whose lead asset, detalimogene, still depends on the ongoing LEGEND Phase 2 trial and a planned BLA submission, leaving substantial clinical and regulatory uncertainty. The prior LEGEND update reportedly fell below expectations across multiple efficacy and durability metrics, prompting a more conservative view with peak penetration reduced to 25% and probability of success set at 30%, while the company faces intense competition from better-resourced peers. Financially, the company continues to burn cash, posting a $32.5M net loss in 3Q26 on $34M of operating expenses, and although it held $266.3M in cash, cash equivalents, and marketable securities as of July 31, 2026, additional equity financing may still be needed, creating dilution risk.